公开(公告)号：US20070275012A1

公开(公告)日：2007-11-29

申请号：US10576158

申请日：2004-10-20

申请人： Julio Aguilar Rubido ,  Enrique Iglesias Perez ,  Yadira Lobaina Mato ,  Daymir Garcia Gonzalez ,  Verena Muzio Gonzalez ,  Gerardo Guillen Nieto ,  Nelson Acosta Rivero ,  Raimundo Ubieta Gomez ,  Julio Alvarez Obregon ,  Santiago Duenas Carrera ,  Carlos Duarte Cano ,  Peter Vanlandshoot ,  Luis Herrera Martinez

发明人： Julio Aguilar Rubido ,  Enrique Iglesias Perez ,  Yadira Lobaina Mato ,  Daymir Garcia Gonzalez ,  Verena Muzio Gonzalez ,  Gerardo Guillen Nieto ,  Nelson Acosta Rivero ,  Raimundo Ubieta Gomez ,  Julio Alvarez Obregon ,  Santiago Duenas Carrera ,  Carlos Duarte Cano ,  Peter Vanlandshoot ,  Luis Herrera Martinez

IPC分类号： A61K39/295 ,  A61P31/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/70 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2740/16034 ,  C12N2770/24234

摘要： The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.

摘要翻译： 本发明涉及针对引起慢性病的病原体的治疗性疫苗领域。 它包括用于治疗含有乙型肝炎表面抗原（HBsAg）作为主要化合物的制剂。 HBsAg作为重组产品在Picchia pastoris中生产。 本发明的制剂还包括乙型肝炎表面抗原和其他共同施用的抗原的组合。 除了特异性抗体的显着反应之外，所得制剂能够产生有效的淋巴细胞扩增和细胞毒性应答，这使得它们在治疗这些疾病方面非常有效。

公开(公告)号：US20080280354A1

公开(公告)日：2008-11-13

申请号：US11486535

申请日：2006-07-14

申请人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

发明人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

IPC分类号： C12N15/63 ,  C07H21/04

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N15/86 ,  C12N2740/16122 ,  C12N2740/16322

摘要： The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.

摘要翻译： 本发明涉及通过所述病毒的不同基因的片段的结合而形成的HIV嵌合基因，其中所述片段含有细胞毒性T细胞（CTL）或HIV-1辅助T细胞的表位，所述表位由广泛的抗原 型主要组织相容性复合物（HLA-I）。 从所述基因获得的重组痘病毒可用于针对HIV / AIDS感染的预防和治疗性疫苗接种，能够在接种疫苗的实验室动物中产生保护性免疫细胞应答，并被HIV / AIDS患者的CTL淋巴细胞识别。

公开(公告)号：US06358933B1

公开(公告)日：2002-03-19

申请号：US09530925

申请日：2000-05-05

申请人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Maria de Jesus Leal Angulo ,  Dagmara Pichardo Diaz ,  Enrique Iglesias Perez ,  Antonieta Herrera Buch ,  Belquis Sandez Oquendo ,  Alexis Musacchio Lasa ,  Diogenes Quitana Vazquez ,  Lissere Crombet Menedez

发明人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Maria de Jesus Leal Angulo ,  Dagmara Pichardo Diaz ,  Enrique Iglesias Perez ,  Antonieta Herrera Buch ,  Belquis Sandez Oquendo ,  Alexis Musacchio Lasa ,  Diogenes Quitana Vazquez ,  Lissere Crombet Menedez

IPC分类号： A61K3170

CPC分类号： A61K39/21 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55583 ,  C12N2740/16034

摘要： The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.

摘要翻译： 本发明涉及一种包含核酸疫苗和免疫增强量的acemannan的制剂，其中所述acemannan在宿主中增强疫苗的免疫应答。 本发明还涉及一种通过施用包含核酸疫苗和acemannan的制剂来增强宿主对核酸疫苗的免疫应答的方法。

公开(公告)号：US07374766B1

公开(公告)日：2008-05-20

申请号：US09857402

申请日：1999-12-01

申请人： Julio César Aguilar Rubido ,  Daniel O. Palenzuela Gardón ,  Verena L. Muzio González ,  Gerardo E. Guillén Nieto ,  Eduardo Pentón Arias ,  Dagmara Pichardo Díaz ,  Enrique Iglesias Perez

发明人： Julio César Aguilar Rubido ,  Daniel O. Palenzuela Gardón ,  Verena L. Muzio González ,  Gerardo E. Guillén Nieto ,  Eduardo Pentón Arias ,  Dagmara Pichardo Díaz ,  Enrique Iglesias Perez

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/12

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/70 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2730/10134

摘要： The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens.The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation.These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced.The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.

摘要翻译： 本发明涉及药物分支，特别是涉及疫苗抗原的新制剂。 本发明所追求的技术目标正是开发能够增强对粘膜施用抗原的免疫应答的制剂，使制剂中化合物的数量最小化，并通过协同相互作用产生强烈的粘膜和系统反应 制剂中的抗原。 这些配方能够：a）扩大抗乙型肝炎免疫反应的谱，含有主要化合物HBsAg和HBcAg，b）通过病毒核衣壳c）增强对HBsAg的反应c）通过粘膜途径产生组合疫苗， HBsAg作为中枢抗原。 可以引入稳定剂和防腐剂。 本发明的制剂可以作为人或兽用疫苗制剂应用于制药工业。

公开(公告)号：US07318927B2

公开(公告)日：2008-01-15

申请号：US10469256

申请日：2002-02-22

申请人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

发明人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

IPC分类号： A61K39/21

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N15/86 ,  C12N2740/16122 ,  C12N2740/16322

摘要： The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.

公开(公告)号：US06355414B1

公开(公告)日：2002-03-12

申请号：US09380790

申请日：2000-01-06

申请人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

发明人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

IPC分类号： C12Q170

CPC分类号： A61K39/095 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/55544 ,  A61K2039/55583 ,  A61K2039/55588 ,  C12N2730/10134 ,  Y10S514/885 ,  Y10S977/906

摘要： The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.

摘要翻译： 本发明涉及药物领域，特别是涉及使用具有疫苗抗原的新辅助制剂。 本发明追求的技术目标正是开发能够增加和/或调节生物体对血清和粘液衬里中的疫苗抗原的免疫应答的制剂。 为此，开发了一种配方，其中包含乙肝病毒的表面抗原和乙酰甘露聚糖的主要成分。 作为该结果的延伸，开发了其中a）将HBsAg用作同源或异源抗原载体b）颗粒抗原的递送系统和c）可溶性抗原与特定比例的acemannan结合的制剂。 本发明的制剂可用于制药工业，作为用于人类和兽医用途的疫苗制剂。